Analyzing the Parkinson's disease clinical trial pipeline to facilitate patient collaboration in research.

PDTrialTracker.info


Site advisor:  Gary Rafaloff, PD Research Advocate, New Jersey, USA

Gary Rafaloff is a businessman and entrepreneur with over 40 years of professional experience in finance, management, organizational consulting and business development. Gary was diagnosed with Parkinson's Disease in 2012 and now devotes much of his time as an ambassador in the Parkinson's community and as an advocate to advance research for new treatments. Gary lives in Marlboro, NJ.

ABOUT THIS SITE

The goal of the PDTrialTracker.info site is to provide visibility into the Parkinson's disease clinical trial pipeline to facilitate collaboration between the PD patient and research communities, thereby accelerating the path to a cure.  PDTrialTracker incorporates clinical trial data from ClinicalTrials.gov, the largest database of privately and publicly funded clinical studies conducted around the world.  It provides pre-filtered, direct links to interactive maps and trial listings on ClinicalTrials.gov so you can easily view active PD trials by trial type (interventional, observational), phase, recruiting status, therapy type, location, and more.  Collaboration opportunities include projects focused on addressing trial funding and recruiting needs, enhancing clinical trial best practices, and involving patients in study planning and design to ensure the greatest chance of successful outcomes.     


​ABOUT US

















CONTACT US

Email Sue Buff at PDTrialTracker@outlook.com with feedback, questions, or suggestions.










Site creator:  Sue Buff, PD Research Advocate, California, USA

Sue Buff is a Parkinson’s care partner and research advocate living in the San Francisco Bay Area.  Her career background is in software product management, and she currently publishes two websites, www.PDTrialTracker.info and www.CalPD.info (California Parkinson's Support Network), to share research and support information with the Parkinson's patient/family community.